Information Provided By:
Fly News Breaks for December 12, 2017
ELGX
Dec 12, 2017 | 04:55 EDT
Piper Jaffray analyst Matt O'Brian assumed coverage of Endologix with an Overweight rating and $7 price target. The analyst views the company as a "solid player" in the abdominal aortic aneurysms space despite some setbacks.
News For ELGX From the Last 2 Days
There are no results for your query ELGX